Acta Oncol. 1998;37(4):331-8.

Interferon and malignant disease--how does it work and why doesn't it always?

Source

Department of Oncology-Pathology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden. dan@deptonc.ks.se

Abstract

Since their first use at the clinic almost 30 years ago. interferons (IFNS) have become an accepted therapy in a range of malignancies. Although IFN All induce remissions in some patients, they are of no benefit, or at best, lead only to minor improvements in the great majority of patients. This review considers possible mechanisms underlying the antitumour effects of IFN, and discusses possible reasons for resistance to IFN therapy in patients with malignant disease.

PMID:: 9743454; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Cancer - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Review Why do so many cancer patients fail to respond to interferon therapy? [J Interferon Cytokine Res. 1996]
Review Why do so many cancer patients fail to respond to interferon therapy?
Einhorn S, Grander D. J Interferon Cytokine Res. 1996 Apr; 16(4):275-81.
Review Apoptosis and cell growth inhibition as antitumor effector functions of interferons. [Med Oncol. 2001]
Review Apoptosis and cell growth inhibition as antitumor effector functions of interferons.
Sangfelt, Strander H. Med Oncol. 2001; 18(1):3-14.
Review How does interferon-alpha exert its antitumour activity in multiple myeloma? [Acta Oncol. 2000]
Review How does interferon-alpha exert its antitumour activity in multiple myeloma?
Grandér D. Acta Oncol. 2000; 39(7):801-5.
Review Interferon treatment of human malignancies--a short review. [Med Oncol Tumor Pharmacother. ...]
Review Interferon treatment of human malignancies--a short review.
Einhorn S, Strander H. Med Oncol Tumor Pharmacother. 1993; 10(1-2):25-9.
Review Interferons and the tumor cell. [Biotherapy. 1996]
Review Interferons and the tumor cell.
Strander H, Einhorn S. Biotherapy. 1996; 8(3-4):213-8.

See reviews... See all...

Cited by 2 PubMed Central articles

Silencing of the XAF1 gene by promoter hypermethylation in cancer cells and reactivation to TRAIL-sensitization by IFN-beta. [BMC Cancer. 2007]
Silencing of the XAF1 gene by promoter hypermethylation in cancer cells and reactivation to TRAIL-sensitization by IFN-beta.
Micali OC, Cheung HH, Plenchette S, Hurley SL, Liston P, LaCasse EC, Korneluk RG. BMC Cancer. 2007 Mar 21; 7:52. Epub 2007 Mar 21.
Current trends in the management of extra-abdominal desmoid tumours. [World J Surg Oncol. 2006]
Current trends in the management of extra-abdominal desmoid tumours.
Papagelopoulos PJ, Mavrogenis AF, Mitsiokapa EA, Papaparaskeva KT, Galanis EC, Soucacos PN. World J Surg Oncol. 2006 Apr 3; 4:21. Epub 2006 Apr 3.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Interferon and malignant disease--how does it work and why doesn't it always?
Interferon and malignant disease--how does it work and why doesn't it always?
Acta Oncol. 1998 ;37(4):331-8.

PubMed
Two regions in the CD80 cytoplasmic tail regulate CD80 redistribution and T cell...
Two regions in the CD80 cytoplasmic tail regulate CD80 redistribution and T cell costimulation.
J Immunol. 1998 Sep 15 ;161(6):2700-7.

PubMed
Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening i...
Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation of risk factors for polyneuropathy in two Italian communities. Italian General Practitioner Study Group (IGPST).
J Clin Epidemiol. 1998 Aug ;51(8):697-702.

PubMed
Increased PGE2 production mediates the in vitro inhibitory effect of the human i...
Increased PGE2 production mediates the in vitro inhibitory effect of the human immunodeficiency virus P24 immunosuppressive heptapeptide Ch7.
Scand J Immunol. 1998 Sep ;48(3):248-53.

PubMed
Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes ...
Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study.
Lancet. 1998 Sep 12 ;352(9131):832-3.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: